This Naked Scientists podcast episode delves into the formidable challenge of lung cancer, a leading cause of cancer-related deaths. It opens with a poignant personal account from former contributor Peter Cowie, highlighting the difficulties of late diagnosis in non-smokers and the temporary success of targeted therapies. Expert insights from oncologists Charlie Swanton and Caroline Dive detail the different types of lung cancer, their causes, symptoms, and the limitations of current treatments, particularly for aggressive small cell lung cancer. The episode explores significant advancements in early detection, such as low-dose CT screening, and discusses cutting-edge therapeutic strategies including immunotherapy and antibody-drug conjugates. Furthermore, it introduces revolutionary diagnostic technology—a sub-millimeter fiber optic endoscope for precise peripheral lung biopsies—and the pioneering Lungvax clinical trial for a cancer vaccine designed to prevent lung cancer development and recurrence by training the immune system to target specific cancer cell "red flags."
Understanding and Fighting Lung Cancer
0:28 Lung Cancer: A Major Killer: The episode focuses on lung cancer, which claims more lives than breast, prostate, and colon cancers combined, often remaining undetected until advanced stages.
1:11 A Personal Story of Late Diagnosis: Peter Cowie, a non-smoker and former tech correspondent, shares his experience with non-small cell lung cancer, diagnosed late with 14 tumors across his body, underscoring the challenge of early detection in never-smokers.
2:20 Targeted Therapy and Its Limitations: Peter benefited initially from osimertinib, a targeted therapy tablet that "switches off" cancer cell division with minimal side effects, allowing him to live an active life. However, resistance eventually developed due to tumor cell diversity and genetic instability.
4:30 Types and Causes of Lung Cancer: Oncologist Charlie Swanton explains the three main types: non-small cell lung cancer (most common), small cell lung cancer, and mesothelioma. Over 90% of cases are linked to smoking, with air pollution and family history also contributing.
5:31 Common Symptoms: Symptoms often include prolonged cough (sometimes with blood), breathlessness, weight loss, and signs of metastatic disease (spread to bones, liver, brain).
6:06 The Challenge of Late Presentation: Lung cancer often presents late, but low-dose CT screening for high-risk individuals (over 55 with a smoking history) has significantly shifted diagnoses to earlier, more curable stages.
6:57 Treatment Approaches: Early-stage disease is primarily treated with surgery, increasingly combined with neo-adjuvant chemotherapy and immunotherapy before surgery for better outcomes. Late-stage disease focuses on palliation, integrating radiotherapy, chemotherapy, and immunotherapy.
9:47 Future Therapeutic Opportunities: Swanton highlights leveraging the immune system and antibody-drug conjugates (antibodies armed with cytotoxic drugs for targeted delivery) as key future directions. He also emphasizes early detection and preventing cancers from emerging.
11:31 Small Cell Lung Cancer (SCLC): The "Ferrari of Cancer": Caroline Dive describes SCLC as the most aggressive lung cancer, rapidly spreading and often detected at advanced stages with secondary tumors. It has a very poor prognosis (7% 5-year survival rate).
12:31 "Shape-Shifting" Tumors: SCLC exhibits high "tumor plasticity," meaning cells can change their appearance and behavior, making treatment challenging. They have a very high rate of cell division.
13:54 SCLC Treatment and Research: Traditional chemotherapy has high toxicities. Immunotherapy offers a 15% response rate, but identifying responders is a current research focus. New models from circulating tumor cells are helping understand SCLC biology, including how tumors evade immune cells.
16:40 Promising SCLC Therapy: T-Cell Engagers: Early clinical trials for T-cell engagers, an immunotherapy that brings immune and tumor cells together, show exciting potential for better responses in SCLC.
18:24 Novel Early Detection: Micro-Endoscopy: Jim Stone introduces a new technology to overcome limitations of traditional bronchoscopy. A sub-millimeter fiber optic endoscope, passing through a conventional bronchoscope, can reach peripheral lung nodules previously inaccessible for direct biopsy.
20:23 "Eyes on the Biopsy": This new endoscope allows clinicians to visually confirm they are biopsying the target tissue, reducing false negatives and aiming to become the gold standard for peripheral lung sampling.
23:52 Advanced Imaging for Tissue Analysis: The system uses fluorescent lifetime imaging, measuring light interaction time with tissue to detect shifts indicating abnormal cells, providing diagnostic information without needing a physical sample.
24:50 Prevention: The Lungvax Cancer Vaccine: Mariam Jamal Hanjani discusses the Lungvax clinical trial, the first in the UK to prevent lung cancer. It aims to train the immune system to recognize and attack "red flags" (abnormal proteins from mutations) found specifically on cancer cells.
27:10 Targeting Recurrent Mutations: Lungvax specifically targets common, recurrent "red flags" in lung cancer, aiming for a universal vaccine rather than patient-specific ones.
29:36 Two-Pronged Prevention Strategy: The vaccine is designed for patients who have undergone curative surgery to prevent relapse by identifying and killing hidden cancer cells, and for high-risk individuals to prevent cancer development in the first place.